Fluorescence Optical Imaging for Treatment Monitoring in Patients With Early and Active Rheumatoid Arthritis in a 1-Year Follow-Up Period

Anne-Marie Glimm; Lisa Ines Sprenger; Ida Kristin Haugen; Ulrich Mansmann; Sandra Hermann; Thomas Häupl; Paula Hoff; Gerd-Rüdiger Burmester; Marina Backhaus; Lien Le; Sarah Ohrndorf

Disclosures

Arthritis Res Ther. 2019;21(209) 

In This Article

Conclusions

In conclusion, activity in FOI phase 1 changed significantly over 1 year under therapy in the group of responders regarding the parameter of clinical remission (DAS28). However, a significant change of FOI phase 1 was also observed in non-responders, so we cannot objectively deduce a therapy response of phase 1. However, the correlation of FOI with ultrasound as a validated and well-established imaging technique in daily rheumatological practice should be emphasized. In the issue, the role of FOI in therapy monitoring needs to be investigated in further studies.

Comments

3090D553-9492-4563-8681-AD288FA52ACE

processing....